Regeneron stock after-hours at EUR 650.25: plus 0.46 percent versus prior close
Published on 10/06/2026 at 20:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron stock was at EUR 650.25 after-hours at 8:09 p.m. CEST on October 6, 2026, up 0.46 percent versus the prior close of EUR 647.25 at Lang & Schwarz.
Trading day in focus
The Lang & Schwarz prior close was EUR 647.25. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Regeneron stock.
Regeneron sets out ESMO research program
In a release dated October 6, Regeneron Pharmaceuticals said it will present new clinical research in 10 abstracts at the European Society for Medical Oncology Congress in Madrid from October 23 through October 27. The program covers cutaneous squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, melanoma and cancer-associated thrombosis, including approximately 3.5-year follow-up data from the Phase 3 C-POST trial of adjuvant Libtayo. GlobeNewswire published the issuer's announcement.
Sanofi collaboration expanded
Separately, Regeneron and Sanofi announced on October 1 an expanded antibody collaboration covering four long-acting antibodies. Regeneron is set to receive a USD 1 billion upfront payment and could receive up to an additional USD 7 billion in development, regulatory and commercial milestone payments. The companies said they will share development and commercialization costs and split future profits equally. Regeneron published the release.
